Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP). - KIVIRID

Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).

Authors: Syvart Dennen, Marty Masek, Paul Cockrum, Ravi Kumar Paluri

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.693

Source: Full article

Abstract

693